ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+51.05%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$154M
AUM Growth
+$154M
(-13%)
Cap. Flow
-$63.5M
Cap. Flow
% of AUM
-41.25%
Top 10 Holdings %
Top 10 Hldgs %
62.2%
Holding
45
New
6
Increased
7
Reduced
17
Closed
11
Top Buys
| 1 |
Ocular Therapeutix
OCUL
|
$12.1M |
| 2 |
Enliven Therapeutics
ELVN
|
$4.79M |
| 3 |
Applied Therapeutics
APLT
|
$1.81M |
| 4 |
Celldex Therapeutics
CLDX
|
$1.66M |
| 5 |
Agios Pharmaceuticals
AGIO
|
$1.62M |
Top Sells
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$23.5M |
| 2 |
Kura Oncology
KURA
|
$13M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$11.6M |
| 4 |
EyePoint Pharmaceuticals
EYPT
|
$9.82M |
| 5 |
Praxis Precision Medicines
PRAX
|
$8.38M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ocular Therapeutix
OCUL
$2.12B
| $24M | 15.58% | 2,635,287 +1,325,287 | +101% | +$12.1M |
|
|
2
Praxis Precision Medicines
PRAX
$958M
| $9.9M | 6.43% | 162,302 -137,334 | -46% | -$8.38M |
|
3
Mersana Therapeutics
MRSN
$36.5M
| $9.7M | 6.3% | 2,164,628 -203,372 | -9% | -$911K |
|
4
Taysha Gene Therapies
TSHA
$797M
| $9.57M | 6.21% | 3,333,333 -256,000 | -7% | -$735K |
|
5
Rocket Pharmaceuticals
RCKT
$354M
| $8.8M | 5.72% | 326,787 -39,228 | -11% | -$1.06M |
|
6
Sarepta Therapeutics
SRPT
$1.78B
| $8.31M | 5.4% | 64,162 -6,438 | -9% | -$833K |
|
7
Vaxcyte
PCVX
$4B
| $7.16M | 4.65% | 104,830 -12,543 | -11% | -$857K |
|
|
8
Enliven Therapeutics
ELVN
$1.2B
| $6.97M | 4.53% | 396,099 +272,223 | +220% | +$4.79M |
|
9
Tourmaline Bio
TRML
$601M
| $5.98M | 3.88% | 261,108 +29,226 | +13% | +$669K |
|
|
10
Applied Therapeutics
APLT
$71M
| $5.39M | 3.5% | 792,000 +266,900 | +51% | +$1.81M |
|
11
Dyne Therapeutics
DYN
$1.92B
| $5.24M | 3.4% | 184,500 +36,664 | +25% | +$1.04M |
|
12
Disc Medicine
IRON
$2.07B
| $4.78M | 3.11% | 76,800 -38,700 | -34% | -$2.41M |
|
13
Revolution Medicines
RVMD
$7.1B
| $4.63M | 3.01% | 143,777 -16,223 | -10% | -$523K |
|
|
14
Celldex Therapeutics
CLDX
$1.47B
| $4.57M | 2.97% | 109,000 +39,600 | +57% | +$1.66M |
|
|
WHWK
15
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $4.33M | 2.81% | 1,849,402 | – | – |
|
16
HilleVax
HLVX
$105M
| $4.17M | 2.71% | 250,609 -73,991 | -23% | -$1.23M |
|
17
Crinetics Pharmaceuticals
CRNX
$2.92B
| $3.67M | 2.38% | 78,403 -9,097 | -10% | -$426K |
|
18
Viridian Therapeutics
VRDN
$1.5B
| $3.49M | 2.27% | 199,433 -82,067 | -29% | -$1.44M |
|
19
Terns Pharmaceuticals
TERN
$609M
| $3.05M | 1.98% | 465,079 -90,181 | -16% | -$592K |
|
20
Immunovant
IMVT
$2.56B
| $2.98M | 1.94% | 92,346 -27,143 | -23% | -$877K |
|
21
Verastem
VSTM
$569M
| $2.44M | 1.59% | 207,095 -25,154 | -11% | -$297K |
|
22
Arcellx
ACLX
$3.85B
| $2.4M | 1.56% | 34,500 -42,500 | -55% | -$2.96M |
|
|
23
Kura Oncology
KURA
$686M
| $1.92M | 1.25% | 90,000 -611,349 | -87% | -$13M |
|
24
Insmed
INSM
$28.8B
| $1.67M | 1.09% | 61,718 +32,218 | +109% | +$874K |
|
|
25
Agios Pharmaceuticals
AGIO
$2.19B
| $1.62M | 1.05% | +55,262 | New | +$1.62M |
|